Business Context and Reporting Period
This Form 8-K reports on the Special Meeting of Stockholders held by Cartesian Therapeutics, Inc. on September 20, 2024. The meeting addressed proposals regarding the conversion of Series B Non-Voting Convertible Preferred Stock and the potential adjournment of the meeting to solicit additional votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved two key proposals at the Special Meeting:
- Proposal 1: Approval of the issuance of Common Stock upon conversion of Series B Non-Voting Convertible Preferred Stock.
- Votes For: 12,514,261
- Votes Against: 150,060
- Votes Abstained: 1,650
- Broker Non-Votes: 0
Note: The tabulation excluded 3,563,247 shares issued in a July 2024 private placement to comply with Nasdaq listing rules, though these shares were eligible under Delaware law.
- Proposal 2: Approval of the adjournment or postponement of the Special Meeting if necessary to continue soliciting votes for Proposal 1.
- Votes For: 16,076,183
- Votes Against: 151,789
- Votes Abstained: 1,246
- Broker Non-Votes: 0
A total of 16,229,218 shares were present electronically or by proxy, representing approximately 75.90% of outstanding Common Stock as of the July 29, 2024 record date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the procedural details of the stockholder vote.
Investor Verification Checklist
- Confirm the final issuance of Common Stock resulting from the conversion of Series B Preferred Stock following the approval of Proposal 1.
- Review the definitive proxy statement filed on August 16, 2024, for detailed terms of the Series B Preferred Stock conversion.
- Verify the impact of the July 2024 private placement shares on the company's total share count and dilution metrics.
- Monitor subsequent filings for the updated capitalization table reflecting the approved conversion.